MRNA's earnings and revenues surpass estimates in the fourth quarter of 2024. The company reiterates 2025 total revenue ...

“Faisal has a proven track record in integrating cutting-edge science with practical, evidence-base PHILADELPHIA, October 24, 2024--New data for AREXVY, GSK’s RSV vaccine, show potential to ...

A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...

Hedge fund Citadel has made a £305mn bet against drugmaker GSK, the biggest short position against the company in more than a decade.

Learn how analytical methodologies can be used to identify RSV pre- and post-fusion proteins for vaccine development.

Sales of GSK's respiratory syncytial virus (RSV) vaccine Arexvy slumped 72% in the third quarter of this year, as narrower recommendations on its use in the US started to have an effect.

Ohio is one of many states experiencing a quad-demic of infections. These 4 viral infections are COVID-19, influenza (flu), ...

GSK's vaccine has just hit the mark in a phase 3 trial, and the company is preparing regulatory filings seeking approval for use in older adults in an attempt to stay ahead of Pfizer and other RSV ...

The vaccine maker Moderna had no Valentine’s Day chocolates for investors when its fourth-quarter financial results came out ...

A clear endorsement from their healthcare provider and being supplied information about recommended vaccines before their ...

GSK, a British drugmaker, recently beat Q4 earnings estimates. The company is our FDI of the Month January 2025.